Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098024 | 0.91 | HTR4 (0.47) | DRD2DRD4DRD3HTR4ACHE | |
| SCHEMBL18094620 | 0.90 | HTR4 (0.42) | DRD2DRD4DRD3HTR4GSK3B | |
| SCHEMBL16123295 | 0.90 | HTR3E (0.51) | DRD2DRD4DRD3HTR4HTR3E | |
| SCHEMBL18094604 | 0.84 | DRD3 (0.38) | DRD2DRD3HTR4HTR3EHTR3B | |
| SCHEMBL16097420 | 0.82 | HTR3E (0.50) | DRD2DRD4DRD3HTR4GSK3B | |
| SCHEMBL16098697 | 0.81 | HTR4 (0.47) | DRD2DRD4DRD3HTR4ACHE | |
| SCHEMBL16099115 | 0.81 | HTR3E (0.51) | DRD2DRD4DRD3HTR4HTR3E | |
| SCHEMBL16102244 | 0.80 | HTR3E (0.54) | DRD2DRD4DRD3HTR4HTR3E | |
| SCHEMBL16097911 | 0.80 | HTR4 (0.47) | HTR4ACHEGSK3BACACBACACA | |
| SCHEMBL18094609 | 0.80 | HTR3E (0.53) | DRD2DRD4DRD3HTR4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790211-B2 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-17 | — | — | US | claimed |
| EP-2976337-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147636-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-09-25 | — | — | WO | claimed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| US-9790211-B2 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-9790211-B2 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| EP-2976337-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147636-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | DRD2 195/4885DRD4 165/4885DRD3 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.